Clinical Efficacy and Safety of Oral Apremilast: Treatment Analysis for Chronic Plaque Psoriasis
Meet Barbhaya, Afiya Modasiya, Anu Patel, Nirav Bapat & Krina Patel · Journal of Pharmaceutical Research International · 2022
Background: Apremilast is an oral, selective phosphodiesterase-4 (PDE-4) enzyme inhibitor, approved by the US-FDA for management of moderate to severe plaque psoriasis. Apremilast belongs to class of drug that function by modulating pro-inflammatory cytokines and have a low molec...
Open access
Research Article
10.9734/jpri/2022/v34i43B36316